BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carter W, Connelly S, Struble K. Reinventing HCV Treatment: Past and Future Perspectives. J Clin Pharmacol. 2017;57:287-296. [PMID: 27654843 DOI: 10.1002/jcph.830] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Scott LJ. Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C. Drugs 2018;78:245-56. [DOI: 10.1007/s40265-018-0864-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
2 Jubel JM, Barbati ZR, Burger C, Wirtz DC, Schildberg FA. The Role of PD-1 in Acute and Chronic Infection. Front Immunol 2020;11:487. [PMID: 32265932 DOI: 10.3389/fimmu.2020.00487] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 17.5] [Reference Citation Analysis]
3 Adams RL, Pirakitikulr N, Pyle AM. Functional RNA structures throughout the Hepatitis C Virus genome. Curr Opin Virol 2017;24:79-86. [PMID: 28511116 DOI: 10.1016/j.coviro.2017.04.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
4 Romero-López C, Berzal-Herranz A. The 5BSL3.2 Functional RNA Domain Connects Distant Regions in the Hepatitis C Virus Genome. Front Microbiol 2017;8:2093. [PMID: 29163393 DOI: 10.3389/fmicb.2017.02093] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
5 Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, Borgia SM, Shafran SD, Workowski KA, Pearlman B, Hyland RH, Stamm LM, Svarovskaia E, Dvory-Sobol H, Zhu Y, Subramanian GM, Brainard DM, McHutchison JG, Bräu N, Berg T, Agarwal K, Bhandari BR, Davis M, Feld JJ, Dore GJ, Stedman CAM, Thompson AJ, Asselah T, Roberts SK, Foster GR. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology 2017;153:113-22. [PMID: 28390869 DOI: 10.1053/j.gastro.2017.03.047] [Cited by in Crossref: 170] [Cited by in F6Publishing: 139] [Article Influence: 34.0] [Reference Citation Analysis]
6 Yang Y, Wu FP, Wang WJ, Shi JJ, Li YP, Zhang X, Dang SS. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China. World J Gastroenterol 2019; 25(44): 6551-6560 [PMID: 31802834 DOI: 10.3748/wjg.v25.i44.6551] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
7 Hu L, Li J, Cai H, Yao W, Xiao J, Li YP, Qiu X, Xia H, Peng T. Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles. Antiviral Res 2017;148:5-14. [PMID: 29074218 DOI: 10.1016/j.antiviral.2017.10.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 Shiels MS, Engels EA, Yanik EL, McGlynn KA, Pfeiffer RM, O'Brien TR. Incidence of hepatocellular carcinoma among older Americans attributable to hepatitis C and hepatitis B: 2001 through 2013. Cancer 2019;125:2621-30. [PMID: 30980394 DOI: 10.1002/cncr.32129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
9 McCabe L, White IR, Chau NVV, Barnes E, Pett SL, Cooke GS, Walker AS; SEARCH investigators. The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam. Trials 2020;21:413. [PMID: 32423467 DOI: 10.1186/s13063-020-04350-x] [Reference Citation Analysis]
10 Lawitz E, Poordad F, Wells J, Hyland RH, Yang Y, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Landaverde C. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus. Hepatology. 2017;65:1803-1809. [PMID: 28220512 DOI: 10.1002/hep.29130] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
11 Heo YA, Deeks ED. Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C. Drugs 2018;78:577-87. [PMID: 29546556 DOI: 10.1007/s40265-018-0895-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
12 Pedersen NC, Kim Y, Liu H, Galasiti Kankanamalage AC, Eckstrand C, Groutas WC, Bannasch M, Meadows JM, Chang KO. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. J Feline Med Surg 2018;20:378-92. [PMID: 28901812 DOI: 10.1177/1098612X17729626] [Cited by in Crossref: 96] [Cited by in F6Publishing: 60] [Article Influence: 19.2] [Reference Citation Analysis]
13 Oliveira-Filho AB, Aires DWF, Cavalcante NS, Raiol NC, Lisboa BLA, Frade PCR, da Costa LM, Pinheiro LML, Machado LFA, Martins LC, Silva-Oliveira GC, Pinho JRR, Kupek E, Lemos JAR. Hepatitis C Virus among Female Sex Workers: A Cross-Sectional Study Conducted along Rivers and Highways in the Amazon Region. Pathogens 2019;8:E236. [PMID: 31739623 DOI: 10.3390/pathogens8040236] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Courtemanche Y, Poulin C, Serhir B, Alary M. HIV and hepatitis C virus infections in Quebec's provincial detention centres: comparing prevalence and related risky behaviours between 2003 and 2014-2015. Can J Public Health 2018;109:353-61. [PMID: 29981093 DOI: 10.17269/s41997-018-0047-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]